Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Cerus Corporation Rose as Much as 16.3% Today

By Maxx Chatsko – May 26, 2017 at 4:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Even with today's pop, the stock is near six-year lows.

What happened

Shares of biomedical products-manufacturer Cerus Corporation (CERS -1.35%) rose over 16% today after investors saw an opportunity in the beaten-down stock. Disappointing results  from the first quarter of 2017, reduced full-year 2017 financial guidance, and the unavailability of a key supporting product used in the production of the company's Intercept platelets, have cut the stock in half in the last month alone. The last event -- which occurred earlier this week -- forced management to once again lower full-year 2017 revenue guidance. 

Despite the setback, financial analysts from across the sector have reiterated their price targets for Cerus Corporation. Cantor Fitzgerald set its price target to $7 per share, down from its earlier $9 per-share target, but which still represents a more than 200% premium from current levels.

Others have even higher price targets and are similarly optimistic about the company's potential. That has injected some confidence into the stock to close out the week. As of 3:27 p.m. EDT, the stock had settled to a 15.6% gain. 

A woman walking through a doorway in the shape of an upward arrow.

Image source: Getty Images.

So what

On May 25, Cerus Corporation told investors that some U.S. blood centers producing its Intercept platelets are experiencing a shortage of platelet additive solution, or PAS. Fresenius Kabi, which produces the device used for manufacturing PAS, discontinued a component of the previous production system, but encountered an unexpected delay in receiving approval from the U.S. Food and Drug Administration for the new plastic part.

Although temporary, the delay is expected to impact Intercept platelet production through the remainder of the year. That's because Intercept platelets can be manufactured in a mixture of either 65% PAS and 35% plasma using the Amicus apheresis platform, or 100% plasma using the Trimal Accel apheresis platform.

While some U.S. blood centers may own both systems, others have standardized platelet production using just one system. That forced management to lower full-year 2017 revenue guidance to a range of $38 million to $46 million. That's down from the previous range of $43 million to $48 million, which itself was lower than the original revenue range of $45 million to $50 million, but it's still at least as good as full-year 2016 revenue, which topped out at $39 million.

The point is that, with swelling losses each year, Cerus Corporation doesn't have a long runway to work with, so every delay increases the pressure on the stock.

Now what

Investors are beginning to think that the sell-off of Cerus Corporation stock was a bit overdone. The company's Intercept platelet platform is growing each year -- although maybe a bit slower than they would like -- and showing good market traction.

Of course, as the Fresenius Kabi component delay demonstrates, the company's success is dependent on the smooth operation of an ecosystem of technologies outside of its control. That has risks, and the market is still figuring out how to price them into the share price.

Maxx Chatsko has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cerus Stock Quote
Cerus
CERS
$3.65 (-1.35%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.